banda transcan 2 2016ul

Title:Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance


Project Coordinator:
Olivier BERNARD (France) INSERM U1170, Institut Gustave Roussy


Project Partners:
Elias CAMPO (Spain) Fundació Privada Clinic per a la Recerca Biomèdica/Hospital Clinic c/Rosello, Barcelona
Thorsten ZENZ (Germany) DKFZ / NCT, Dept. of Translational Oncology, Heidelberg
Wolfgang HUBER (Germany) European Molecular Biology Laboratory (EMBL), Heidelberg
Kostas STAMATOPOULOS (Greece) Institute of Applied Biosciences, CERTH | Center for Research and Technology Hellas, Thessaloniki
Paolo GHIA (Italy) Università Vita-Salute San Raffaele, Milan
Gonzalo R. Ordonez (Spain) DREAMgenics Parque Tecnológico de Asturias, Llanera, Asturias


Project Abstract:
a. Background and rationale: The clinical course and eventual outcome of Chronic Lymphocytic Leukemia (CLL) patients is highly variable. It is accepted that intratumor genetic and cellular heterogeneity is the main force driving both tumor development and treatment resistance. At the genetic level, there is no single gene mutation characteristic of the disease and CLL cells in a given patient may carry different burden of different mutations affecting different pathways. At the cellular level, leukemic cells remain responsive to multiple stimuli originating from microenvironment but with different intensity and effect. Available biomarkers aiming at predicting both the disease course and the response to treatment exist, but none of the current models capture the complexity of intratumor heterogeneity.
b. Hypothesis: Intratumor genetic and cellular heterogeneity of CLL has tremendous implications for treatment and outcome, but is currently poorly understood. Novel means of observing and quantifying this heterogeneity together with integrative and predictive mathematical modeling will help identifying strategies to prevent treatment resistance.
c. Aims:
- To comprehensively characterize the biological and cellular heterogeneity of CLL, at the intratumor level, and evaluate its impact on disease evolution and response to therapy. Samples from different involved tissues and at different time points during CLL evolution, including stable, progressive, and relapsed after treatment will be used.
- To monitor cellular response to drug exposure in vitro in a large-scale study of genetically characterized primary CLL cells, from different tissues, with and without microenvironmental stimuli, to obtain robust data on the impact of mutations load and other biomarkers on drug response.
- To integrate data of different types and scales with clinical information, including response to treatment, using up to date bioinformatics and mathematical modeling approaches.
d. Methods: Cellular and molecular biology methods, advanced data analytics and mathematical modeling.
e. Expected results and potential impact: We propose a concerted effort combining genomic technologies, cellular biology approaches, statistical analysis and mathematical modeling that will build a comprehensive framework to establish the role of intratumor heterogeneity in the progression of the tumor, modulation of the response to the treatment and development of resistance. The integrated analysis proposed here will allow the development of robust predictive tools for monitoring CLL from diagnosis to the different steps in the evolution of the disease. This project is ideally timed and positioned to exploit a paradigmatic age-related malignancy with marked intratumor heterogeneity, heterogeneous clinical course and response to treatment.

(Project funded under JTC 2014)


TRANSCAN-2 News


Fourth Joint Transnational Call 2017 (JTC 2017)

on: Translational Research on Rare Cancers

12 projects selected for funding

visit the page

Newsletters

Newsletter 7, October 2018

Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, December 2017
Newsletter 3, September 2017
Newsletter 2, April 2017
Newsletter 1, December 2016

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.